Literature DB >> 1692161

Treatment options for recurrent lymphomas.

R I Fisher1, P J Stiff.   

Abstract

The prognosis of patients with aggressive non-Hodgkin's lymphomas who fail to achieve a complete remission or who relapse following initial chemotherapy has improved dramatically in recent years. Bone marrow transplantation now provides a curative option and is the current treatment of choice. Conventional chemotherapeutic regimens are not capable of salvaging these patients; however, most patients should be treated with chemotherapy to induce a temporary remission prior to the transplantation procedure. Numerous studies are currently attempting to improve preparative chemotherapy and/or radiation therapy. Since conventional chemotherapy provides short-term palliation only, patients who are not candidates for transplantation should be entered into investigational protocols.

Entities:  

Mesh:

Year:  1990        PMID: 1692161

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  1 in total

1.  Cytosine arabinoside and etoposide (CARE) in relapsed and refractory non-Hodgkin's lymphoma.

Authors:  R Mansberg; J Gibson; D E Joshua; H Kronenberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.